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Abstract
Chronic obstructive pulmonary disease (COPD) is a chronic and progressive disease that
has been associated with high mortality rates and is now becoming an economic burden on
public health (WHO, 2012). Tiotropium and long-acting beta2-agonists (LABA) are both
utilized in managing patients with COPD. However, guidelines do not specify which medication
is the drug of choice. To investigate the efficacy of LABA versus Tiotropium, a search of the
current literature was undertaken. The database utilized was the Cochrane Library. Three
systematic reviews were found and all included randomized control trials with similar
methodology. Based on the analysis and synthesis of these reviews, no valid conclusions could
be drawn with regard to the superiority of tiotropium or LABA in managing quality outcomes.
Implications for clinical practice include possibly prescribing both tiotropium and a LABA for a
trial period to allow the patient to decide which medication is better.
Keywords: COPD, tiotropium, LABA, treatment, prevention
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Background
Chronic obstructive pulmonary disease (COPD) is a respiratory disease that is
characterized by chronic and progressive airflow obstruction, cough, shortness of breath and
sputum production (GOLD, 2011). It affects more than 20% of adults over the age of 40 years
with those aged greater than 65 years being four times more likely to have COPD compared to
those aged 45-64 years (Stoller, 2012). Formerly a disease found only in men, the percentage of
women who are being diagnosed with COPD rapidly increased from 2002 to 2012 (Stoller,
2012). In fact, the number of women who died from COPD in 2002 exceeded those in men
(Stoller, 2012). According to the World Health Organization (WHO) (2012), it is estimated that
more than sixty five million people are now living with moderate to severe COPD. In 2002,
COPD was the fifth leading cause of death in the world but by 2030, it is projected to become the
third leading cause of death worldwide (WHO, 2012).
COPD is comprised of two diseases: chronic bronchitis and emphysema (GOLD, 2011).
Emphysema is a disease in which the air sacs of the lungs are gradually destroyed which leads to
the surface area of the lungs being markedly reduced (Mayo Clinic, 2011). In addition,
emphysema also causes narrowing of the terminal bronchioles by destroying the elastic fibers
that enable the small airways to be kept open (Mayo Clinic, 2011). Bronchitis involves chronic
swelling and inflammation of the mucous membranes of the bronchial tubes that lead into the
lungs (Mayo Clinic, 2011). All these changes occur because of an insult of noxious particles or
gases (Karner & Cates, 2012). Cigarette smoke is one of the major risk factors for COPD along
with indoor or outdoor air pollution, occupational dusts and chemicals, and a hereditary alpha-1
antitrypsin deficiency (GOLD, 2011). There are additional other factors that may affect lung
growth during the gestational period and in childhood (GOLD, 2011).
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The signs and symptoms of COPD can vary depending on which of the diseases,
emphysema or chronic bronchitis, is more prominent (Mayo Clinic, 2011). Breathlessness,
wheezing, chest tightness, chronic cough, and mucus production are the clinical symptoms
associated with COPD (Mayo Clinic, 2011). Due to its slow onset and under recognition, COPD
is under diagnosed (GOLD, 2011).

Spirometry is the most important lung function test to

diagnose COPD (Mayo Clinic, 2011). It assesses the degree of airflow limitation and classifies
COPD into four stages: mild, moderate, severe, and very severe (GOLD, 2011). A postbronchodilator FEV1/FVC < 0.70 (normal is 0.70-0.80) on spirometry confirms a diagnosis
(GOLD, 2011). To date there is no cure for COPD, however, it is a preventable and treatable
disease (GOLD, 2011). Management of COPD is multi-faceted and revolves around smoking
cessation, education, pharmacological interventions, and pulmonary rehabilitation (Chong,
Karner, & Poole, 2012).
Because of its chronic and progressive nature, COPD represents a substantial and
mounting economic burden on public health. In the United States, COPD accounts for roughly
1.5 million emergency department visits, 726,000 hospitalizations, 119,000 deaths, and $32
billion in direct and indirect costs annually (Dalal, Shah, D’Souza & Mapel, 2011). Most of the
cost of COPD is due in part to managing and preventing COPD exacerbations. Therefore,
utilizing appropriate pharmacologic treatments in the management and prevention of COPD is
prudent and are the primary goals of therapy (Karner & Cates, 2012).
Current guidelines recommend the use of either a long-acting anticholinergic, such as
tiotroprium or a LABA as first line therapy for persistent or worsening breathlessness (GOLD,
2011). Tiotropium is an anticholinergic that works by blocking the action of acetylcholine which
results bronchodilation (Karner & Cates, 2012). LABA’s works by activating beta2-receptors
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within the smooth muscles of the airway leading to a cascade of events that ultimately causes
bronchodilation (Karner & Cates, 2012).

Over the years, tiotropium has gained widespread

acceptance for being a once daily maintenance therapy for people with stable COPD (Karner &
Cates, 2012). However, the guidelines do not specify if tiotropium is superior to an LABA or in
conjunction with an LABA in stabilizing COPD (Barr, Bourbeau, & Camargo, 2008; Chong,
Karner, & Poole, 2012; Karner & Cates, 2012). The topic of this paper is to evaluate the
evidence on the utility of tiotropium alone, LABA alone, or in conjunction with a LABA on
quality of life, exacerbations, symptoms, lung function and serious adverse events in patients
with COPD.
Analysis
Karner & Cates (2012) investigated the long-term effects of tiotropium when used in
combination with a LABA compared to using either a LABA or tiotropium alone. The authors
did an extensive database search of respiratory journals, clinicaltrials.gov, manufacturers’
websites, and the Cochrane Airways Group Specialized Register of trials (CAGR). CAGR is a
database that is derived from systematic searches of databases from the Cochrane Central
Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, and
PyschINFO.
Five randomized, parallel group, placebo-controlled trials were included in this
systematic review. Four of the trials were double-blinded with only one trial being partially
blinded. The length of the studies ranged from 12 weeks to one year of treatment and all were
multi-center studies; three were conducted in several different countries, one was conducted in
27 Canadian medical centers, and another was conducted in 35 centers across the United States.
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The sample consisted of 3,473 participants with a mean age varying between 63 and 68 years.
Gender distribution also varied between 54% and 79% being males. All five studies included
participants who had moderate to severe COPD with the mean baseline lung function varying
between 38% and 52% (Karner & Cates, 2012).
For the intervention, all five studies used 18 µg of tiotropium, one inhalation daily. The
LABA choice varied amongst the studies: salmeterol 25 µg/puff, two puffs twice daily,
indacaterol 150 µg once daily, formoterol 12 µg twice daily and 10 µg twice daily. Regardless of
the interventions, the studies did allow other co-treatments to be utilized which included
salbutamol, inhaled corticosteroids, oxygen, antileukotrienes and methylxanthines (Karner &
Cates, 2012).
The outcomes measures that Karner and Cates (2012) looked at were divided between
primary outcomes and secondary outcomes. Quality of life, hospital admissions, mortality and
disease specific mortality all constituted the primary outcomes. The secondary outcomes looked
at FEV1, exacerbations, symptoms, serious adverse events, disease specific adverse events, and
withdrawals. Dichotomous data variables (i.e. mortality and withdrawals), were analyzed using
odds ratios and were combined using Mantel-Haenzsel odds ratios with a 95% confidence
intervals, with a fixed-effect model. If the events were rare, Peto odds ratio was employed.
Generic Inverse Variance model was utilized in cases where treatments of effects were reported
(Karner and Cates, 2012).
In the treatment group LABA plus tiotropium compared to tiotropium alone, Karner and
Cates (2012) found a slightly larger improvement in the mean quality of life when both
medications were used concurrently (95% CI -2.93 to -0.29). However, in the other two primary
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outcomes, hospital admissions and mortality, no significant differences were found. For
secondary outcomes, the authors noted a statistically significant improvement in the prebronchodilator FEV1 with LABA plus tiotropium (95% CI 0.05 to 0.09) with none of the other
secondary outcomes showing any significant differences. In the LABA plus tiotropium versus
LABA group, formoterol was used and Karner and Cates (2012) found no real significant
differences with any of the outcomes. Furthermore, a one year study by Karner and Cates (2012)
also looked at the cost effectiveness of tiotropium within a Canadian healthcare system and
based on 2006 prices, found tiotropium to be more cost effective compared to tiotropium plus
LABA.
Barr, Bourbeau and Camargo (2008) also wanted to look at the efficacy of tiotropium
when compared to a placebo, ipratropium bromide, and to LABA in patients with stable COPD.
An extensive search of CAGR, respiratory journals, and LILACS was performed by the authors
with the searches being current as of October 2004. Nine studies met the author’s inclusion
criteria. Of these nine studies, seven compared tiotropium to placebo, one compared tiotropium
to ipratropium, and one compared tiotropium to a placebo as well as to salmeterol.
All nine studies were randomized, parallel, double-blinded RCT’s. The combined sample
consisted of 6,584 adult participants. All participants had stable COPD with those who had other
lung disease such as asthma, cystic fibrosis, and bronchiectasis being excluded. The participants
were aged greater than 35 years with the mean age varying between 61 and 68 years. Gender
distribution varied between 57% and 99% being males. The length of studies varied from one
month to 12 months with a weighted mean duration of 6.3 months. All were multi-center studies
with the mentioned settings consisting of the United States, US Veterans’ Administration
Medical Center, Belgium, and Netherlands. Two of the studies did not cite specific countries
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where the research was performed but noted one was conducted in 18 countries while the other
was conducted in 12 countries (Barr, Bourbeau & Camargo, 2008).
Tiotropium 18 µg one inhalation daily was utilized as the intervention in all nine RCT’s.
One study employed salmeterol 50 µg twice daily while the dosage of choice for ipratropium was
40 µg four times a day in another study. In addition, all the studies allowed the use of shortacting β2-agonists and inhaled corticosteroids as co-treatments (Barr et al., 2008).
Barr et al. (2008) analyzed the data using the Cochrane Review Manager RevMan 4.2.
All nine studies were grouped together to yield weighted mean differences (WMD) or odds
ratios. Reporting was done employing a 95% confidence interval. The authors found that
tiotropium did reduce COPD exacerbations compared to placebo (OR 0.75; 95% CI 0.66 to 0.85)
as well as when compared to ipratropium (OR 0.64; 95% CI 0.44 to 0.92). However, there was
not a statistically significant difference (OR 0.88; 95% CI 0.65 to 1.17) between the tiotropium
and salmeterol groups.
Hospitalizations for COPD exacerbations were reduced within the tiotropium group when
compared to a placebo (OR 0.65; 95% CI 0.50 to 0.85); however, there was no real statistically
significant difference in the ipratropium (OR 0.59; 95% CI 0.32 to 1.09) and salmeterol (OR
0.59; 95% CI 0.29 to 1.23) groups. Additionally, all nine RCT’s did not find any statistically
significant differences among all three groups when looking at mortality (OR 0.73; 95% CI 0.35
to 1.49). Furthermore, the confidence interval was wide which was attributed to small numbers
(Barr et al., 2008).
Based on the secondary outcomes, the use of tiotropium showed a statistically significant
improvement in the St. George’s Respiratory Questionnaire (SGRQ) and in the transitional
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dyspnea index (TDI) when compared to placebo (WMD -3.3; 95% CI -4.6 to -0.8 and OR 1.96;
95% CI 1.58 to 2.44) and ipratropium (WMD -3.3; 95% CI -3.2 to -1.0 and OR 2.01; 95% CI
1.26 to 3.20). When comparing tiotropium to salmeterol, there was a slight improvement in
SGRQ and TDI but it was not statistically significant (WMD -3.3; 95% CI -4.7 to -2.2 and OR
1.08; 95% CI 0.80 to 1.46). Improvements in spirometric indices from baseline were greater and
more statistically significant with tiotropium compared to placebo and ipratropium whereas there
was a smaller but still statistically significant improvement when compared to salmeterol.
Finally, dry mouth was the only adverse event that was reported with sufficient consistency and
was greatest in the tiotropium group (Barr et al., 2008).
In the third systematic review, Chong, Karner, and Poole (2012) compared tiotropium
bromide alone to LABA alone against measures of quality of life, exacerbations, lung function,
and serious adverse events in people with COPD. In addition, these authors also looked at the
cost benefit of using tiotropium alone compared to a LABA. The authors extensively searched
CACR, respiratory journals, meeting abstracts, clinicaltrials.gov, and manufacturers’ websites
for research studies as well as NHS EED and HEED for economic evaluations.
Seven clinical studies were included in this review but only six were used in the pool
analysis of data. All studies compared tiotropium to a LABA: four studies used salmeterol, one
study employed formoterol, and another study utilized indacaterol. The sample size consisted of
12, 223 participants with COPD. The mean age ranged between 60 and 65 years with males
constituting the majority of the participants. All the studies used tiotropium 18 µg once daily
and were double-blinded in design except for two studies where a placebo form of tiotropium
was not available. The studies that evaluated tiotropium with salmeterol utilized salmeterol 50
µg with the length of the studies varying from 12 weeks to one year. Formeterol 10 µg was used
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over a six month period whereas indacaterol 150 µg and 300 µg were used over a period of 26
weeks (Chong, Karner & Poole, 2012).
Data was analyzed using the Cochrane Review Manager (RevMAN 5.1) software. As
previously mentioned in the Karner and Cates (2012) review, Chong et al. (2012) also analyzed
dichotomous data variables with Mantel-Haenzsel odds ratios using a fixed-effect model with a
95% confidence interval. Peto odds ratio was utilized in cases where events were rare. A fixedeffect mean difference with a 95% confidence interval was used in cases where continuous data
needed to be analyzed (Chong et al., 2012).
For quality of life, the authors did not pool that data together due to a high level of
heterogeneity. In the authors’ review, two of the studies found indacaterol to be more
statistically significant in improving SGRQ results over tiotropium. On the other hand, two other
studies found a non-statistical difference with salmeterol or formoterol compared to tiotropium.
COPD exacerbations were shown to be lower within the tiotropium group (OR 0.86; 95% CI
0.79 to 0.93) however, one of the largest studies included in the review did show significant
difference. Hospital admissions related to COPD exacerbations were found to have no statistical
difference within three of the studies (OR 0.93; 95% CI 0.57 to 1.54) whereas four of the studies
revealed a significant lower rate of hospital admissions in the tiotropium group (OR 0.87; 95%
CI 0.77 to 0.99). There were no significant difference in FEV1 (MD 10.53; 95% CI -11.47 to
32.51) and TDI score (MD -0.22; 95% CI -0.63 to 0.19) between tiotropium and LABA. Serious
adverse events and withdrawal rates were lower in the tiotropium group (Chong et al., (2012).
Chong et al. (2012) also looked at six economic evaluations that assessed the cost and
cost-effectiveness of tiotroprium 18 µg daily compared to salmeterol 50 µg twice daily. The
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studies were based either on Markov model, an economic model, or on empirical analysis of data
obtained from RTC’s. The settings of these studies took place in a primary or secondary care in
Greece, UK, Netherlands, Spain, and the United States. All studies looked at the maintenance
costs and costs of exacerbation which included respiratory medications, laboratory visits,
physician visits, visits to the emergency department, and hospitalizations. Tiotropium was found
to be linked with lower annual total costs compared to salmeterol in three of the studies. In
another study, tiotropium was associated with a higher cost but also with the highest expected net
benefit within acceptable values for the willingness to pay value. Notwithstanding, two studies
did not compare tiotropium directly to salmeterol but instead drew conclusions regarding costs
indirectly by comparing tiotropium to a no treatment group. Overall, uncertainty does surround
these results based on the sensitivity analysis of the findings found in the various studies.
In this literature review, three similar systematic reviews were able to be utilized. All
three reviews had similar purposes in evaluating the efficacy of tiotropium either alone or in
conjunction with LABA in patients with COPD (Barr, Bourbeau, & Camargo, 2008; Chong,
Karner, & Poole, 2012; Karner & Cates, 2012). All studies were conducted in multiple centers
across numerous countries which allowed the samples to be well represented with a diverse
population. However, none of the reviews fully depicted what percentages of ethnicities were
involved or what socioeconomic classes were included. In addition, all the studies had roughly
identical designs with regard to inclusion and exclusion criteria surrounding disease severity,
age, smoking history, and baseline lung function all of which supports the quality of evidence
found in these reviews. It is important to note that some of the studies were referenced in more
than one systematic review (Barr, Bourbeau, & Camargo, 2008; Chong, Karner, & Poole, 2012;
Karner & Cates, 2012).
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All studies had participants with COPD take different medications (tiotropium,
salmeterol, ipratropium, formoterol, indacaterol). Since these medications were already
approved for use in COPD patients and co-treatments were allowed as well as all participants
were randomly assigned to the different treatment groups; this created a low risk, high risk
benefit ratio and the studies were deemed safe (Barr, Bourbeau, & Camargo, 2008; Chong,
Karner, & Poole, 2012; Karner & Cates, 2012). All studies were RCT’s with most having a
double-blind design. Unfortunately there were a few studies that were partially blinded due to
tiotropium not being available in a blinded format. Chong et al. (2012) and Karner and Cates
(2012) did address this issue in their review.
Two of the systematic reviews found no statistical significance in reducing COPD
exacerbations with tiotropium over other LABA’s (Chong, Karner, & Poole, 2012; Karner &
Cates, 2012). The study by Barr et al. (2008) did show statistical significant with tiotropium
over placebo and ipratropium but no significant difference with comparing tiotropium to
salmeterol. All three reviews found no statistical variation in any of the treatment groups
regarding hospitalizations and mortality (Barr, Bourbeau, & Camargo, 2008; Chong, Karner, &
Poole, 2012; Karner & Cates, 2012). In Karner and Cates (2012), the authors found no statistical
significance for adverse events in either of its treatment groups; however, Chong et al. (2012) did
find a small but statistical difference in rate of adverse events within the tiotropium group over
the LABA group. Furthermore, Barr et al. (2008) also showed statistical difference in the
tiotropium group.
Two studies looked at withdrawal rates with Karner and Cates (2012) finding no real
significant difference whereas Chong et al. (2012) showed a slightly lower withdrawal rate in the
tiotropium group. Comparing the two reviews that looked at TDI scores, Chong et al. (2012)
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found no statistical difference but Barr et al. (2008) did find statistical differences with
tiotropium over placebo, ipratropium and salmeterol. All three reviews found varied results
pertaining to which medication improved quality of life for COPD patients: Barr et al. (2008)
found statistical significance with tiotropium compared to placebo and ipratropium; Karner and
Cates (2012) revealed a significant difference when tiotropium was used in conjunction with a
LABA, and Chong et al. (2012) found no real difference overall in their review. Lastly,
spirometric indices were found to be significantly improved in the tiotropium group in two of the
reviews.
These statistics are clinically relevant as the reviews demonstrated that in general,
tiotropium is not a superior drug compared to LABA’s. No real patterns emerged from these
reviews as each one found different results. Because of a lack of consistency among the three
reviews, a strong argument cannot be made to recommend tiotropium as the first drug of choice
to be utilized in COPD patients. Overall, the reviews had strong methodology by incorporating
large sample sizes, similar designs, similar evaluation tools, and biases were addressed.
Synthesis
Based on the examination of these three systematic reviews all results were related to the
variable of interest in terms of discovering whether tiotriopium, LABA, or a combination of both
were more of a benefit for patients with COPD (Barr, Bourbeau, & Camargo, 2008; Chong,
Karner, & Poole, 2012; Karner & Cates, 2012). Unfortunately, the results were not consistent
across the reviews therefore making it difficult to state with authority that one drug is more
beneficial to these patients over others. Barr et al. (2008) and Chong et al. (2012) did show
COPD exacerbations to be reduced in the tiotropium group; however, results were not found to
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be statistically significant. A majority of the findings were of no statistical difference except for
Barr et al. (2008) saw a statistical difference in SGRG with the combination tiotropium and
LABA. In addition, Chong et al. (2012) saw a statistical significant improvement in spirometric
indices with tiotropium compared to placebo, ipratropium, and salmeterol.
From a social justice perspective, the results from these studies were based on patients
who had moderate to severe COPD (Barr, Bourbeau, & Camargo, 2008; Chong, Karner, &
Poole, 2012; Karner & Cates, 2012). Since patients with mild or very severe COPD were not
included, this can lead to unequal treatment for patients who are at different stages of the disease.
In some cases, patients with mild COPD may be asymptomatic, however, may in the long run
benefit from these medications if they were initialized at an early stage of the disease. When
treating these patients, it is essential for providers to take into consideration the severity of the
disease, the different medications such as tiotropium or a LABA and to compare the benefit to
harm ratio. Providing education to patients will not only make the patient feel more in control of
their disease but will also allow the provider to give holistic care. In addition, the cost of these
medications will affect patients who are in the lower socioeconomic class or are uninsured.
Overall, the studies had different levels of statistical differences with regards to each
outcome but they all showed efficacy of utilizing any one of the medications that were reviewed.
Depending on what the patient or provider is looking at to control, these results will aid them in
their decision making process.
Summary of Recommendations
Based on this literature review, no one drug drastically produced statistically significant
results across all three studies (Barr, Bourbeau, & Camargo, 2008; Chong, Karner, & Poole,
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2012; Karner & Cates, 2012). Certain drugs were shown to be more beneficial to specific quality
outcomes. Therefore, advance nurse practitioners may want to reflect on the findings to
understand which medication may be more suitable for achieving a specific outcome. Because
tiotropium was not shown to be superior to LABA’s in controlling COPD symptoms, advance
nurse practitioners could reasonably perform a medication trial for their COPD patients allowing
them to use one or the other, tiotropium or LABA, each for 1 week to help decide which
medication is more appropriate and convenient for them.
Tiotropium was found to be more cost effective when compared to salmeterol, however,
this result is not truly well represented due to location of study and size of sample (Chong et al,
2012). As a result, advance nurse practitioners need to be aware of which medications are less
expensive, especially when it comes to caring for patients with financial constraints. Properly
educating patients about COPD and medication treatments is essential in providing the highest
quality of care. Patient education contributes to patient empowerment in controlling their disease
and may ultimately lead to improved health care outcomes.
Since all three studies were conducted on patients with moderate to severe COPD, further
research is indicated to assess the role these medications play in patients who have mild and
severe forms of COPD. In addition, longer studies are needed to study the benefits and longterm effects. Chong et al (2012) suggest further research should be conducted at comparing
various dosages of the same drug in order to assess efficacy. Furthermore, more trials are needed
to compare these drugs alone or in combination with inhaled corticosteroids.
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